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Abstract
Background A 7-month-old male infant was admitted be-
cause he was suffering from nephrotic syndrome, along with
encephalomyopathy, hypertrophic cardiomyopathy, clinically
suspected deafness and retinitis pigmentosa, and an elevated
serum lactate level.
Methods CoenzymeQ10 supplementation was started because
of the clinical suspicion of primary CoQ10 deficiency. Despite
intensive efforts, he passed away 4 weeks after admission.
Results The results of genetic tests, available postmortem,
explored two hitherto undescribed mutations in the PDSS2
gene. Both were located within the polyprenyl synthetase do-
main. Clinical exome sequencing revealed a heterozygous
missense mutation in exon 3, and our in-house joint-analysis
algorithm detected a heterozygous large 2923-bp deletion that
affected the 5 prime end of exon 8. Other causative defects in
the CoQ10 and infantile nephrosis-related genes examined
were not found. A postmortem histological, immunohisto-
chemical, and electron microscopic evaluation of the glomer-
uli revealed collapsing-sclerosing lesions consistent with dif-
fuse mesangial sclerosis. The extrarenal alterations included
hypertrophic cardiomyopathy and diffuse alveolar damage. A
histological evaluation of the central nervous system and skel-
etal muscles did not demonstrate any obvious abnormality.
Conclusions Until now, the clinical features and the mutational
status of 6 patients with aPDSS2 gene defect have been reported
in the English literature. Here, we describe for the first time
detailed kidney morphology features in a patient with nephrotic
syndrome carrying mutations in the PDSS2 gene.
Keywords CoQ10 . PDSS2 . Diffusemesangial sclerosis .
Nephrotic
Introduction
Coenzyme Q10 (CoQ10) deficiency is a rare, clinically hetero-
geneous autosomal recessive disorder caused by mutation in
any of the genes that encode proteins directly involved in the
synthesis of the Q10 coenzyme CoQ10, also known as ubiqui-
none. Ubiquinone is a small lipophilic molecule located in the
inner mitochondrial membrane that is primarily involved in
the mitochondrial respiratory chain, where it carries electrons
from complexes I and II to complex III. It is also an important
antioxidant, a cofactor in the biosynthesis of pyrimidines, and
it plays a role in the maintenance of body temperature [1]. The
CoQ10 biosynthesis pathway is complex and has not been
completely clarified. It requires at least 15 genes in humans,
8 of which (PDSS1, PDSS2, COQ2, COQ4, COQ6, ADCK3,
ADCK4, and COQ9) are known to be associated with primary
CoQ10 deficiency (MIM 607426) [2, 3]. Acosta et al. have
recently suggested that the genetic defects of the CoQ10 bio-
synthetic pathway should be classified into three groups [4].
The first group includes PDSS1, PDSS2, COQ2, COQ6, and
ADCK4, and they are associated with glomerular renal in-
volvement that manifests as the steroid-resistant nephrotic
syndrome. This syndrome may be an isolated finding or it
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may be associated with neurological or systemic manifesta-
tions. The second group comprises COQ4, COQ7, and
COQ9, and the main clinical feature is encephalomyopathy.
Other manifestations include hypertrophic cardiomyopathy,
lactic acidosis, and (if renal involvement is present)
tubulopathy. The third group contains ADCK3 and the main
clinical feature is cerebellar ataxia.
The PDSS2 gene encodes the decaprenyl diphosphate syn-
thase subunit 2, responsible for the synthesis of the decaprenyl
tail of CoQ10. The gene forms a heterotetramer with the
PDSS1 gene. In 2000, Rötig et al. reported three siblings with
similar symptoms, but with different degrees of severity [5].
They displayed the nephrotic syndrome, neurological impair-
ment (ataxia, dystonia, amyotrophia), retinitis pigmentosa,
sensorineural deafness, and cardiomyopathy. Trans-
prenyltransferase deficiency was identified, which was subse-
quently shown to be caused by a mutation in the PDSS2 gene
[6]. CoQ10 therapy was administered in two siblings and this
improved their condition. Since then, PDSS2 mutations have
been identified in 3 other patients, all with nephrotic syn-
drome, 1 with compound heterozygous mutations [7], and 2
with homozygous mutations [8]. As renal biopsy was not
performed in any of the patients with PDSS2 mutations, the
histological changes responsible for the nephrotic syndrome
remained undescribed. Here, we report a deceased male infant
with nephrotic syndrome, multiorgan failure, and clinical sus-
picion of primary CoQ10 deficiency. The results of genetic
testing, available postmortem, explored two new, unpublished
PDSS2 mutations that were considered to be the cause of his
fatal disease. The autopsy evaluation of glomeruli revealed
diffuse mesangial sclerosis.
Materials and methods
Clinical history
Our male infant was the f i rs t ch i ld of heal thy,
nonconsanguineous Caucasian parents. He was born after an
uncomplicated pregnancy in the 38th gestational week by ce-
sarean section, weighing 3,150 g with an Apgar score of 9/9.
He had a variety of mild symptoms from birth. During the
newborn screening procedure, his transient otoacoustic emis-
sion was abnormal; thus, he was put on the waiting list for
brainstem evoked response audiometry scheduled at the age of
6 months. Continuous mild inspiratory stridor warranted di-
rect laryngoscopy, but this revealed a normal anatomy.Weight
gain was poor, the stool was never normal, being usually
odorous, fluid-like, or mucous. Cystic fibrosis was suspected,
but the 18 most frequent mutations in CFTR gene were ex-
cluded. At 6 months of age, he underwent a bilateral inguinal
hernia operation. Afterward, he developed mild lower leg
edema and he was frequently crying. Then he was referred
to our hospital at 7 months of age.
Upon admission, he had general edema, muscle hypo-
tonia, mild inspiratory stridor, and global developmental
delay. He did not react to auditory stimuli, and we detect-
ed no tracking and focusing eye movements. Surprisingly,
these symptoms had not been noticed by his parents.
Laboratory findings disclosed low serum Na (126 mmol/
l), Cl (88 mmol/l), hypoproteinemia (total protein 32 g/l,
albumin 16 g/l), dyslipidemia (serum triglyceride, choles-
terol, and LDL cholesterol levels were 3.2, 7.6, and
4.6 mmol/l respectively), anemia, elevated lactate (8–
10 mmol/l), and pyruvate (160 μmol/l). The CK, LDH,
GOT, and GPT values were normal. Urinalysis revealed
proteinuria; initially 90 mg/dl, it rose to a peak of
1,470 mg/dl. He had mild hypothyreosis and a high aldo-
sterone level, the latter most likely being due to the
hyponatremia. The blood pressure measurements revealed
moderate hypertension (range 80/60–110/70 mmHg). A
chest X-ray indicated right-sided hydrothorax and
cardiomegaly. Echocardiography revealed pulmonary hy-
pertension and severe left ventricular hypertrophy; the in-
terventricular septum being 18 mm thick. An electroen-
cephalogram identified nonspecific encephalopathic signs.
Ophthalmology and a visual-evoked potential study sug-
gested retinitis pigmentosa, whereas otoneurology found
no outer haircell activity.
The markedly elevated serum lactate level, the
infantile-onset nephrotic syndrome, the suspected enceph-
alomyopathy, deafness, and retinitis pigmentosa, and the
hypertrophic cardiomyopathy, all strongly suggested
CoQ10 deficiency. Although we immediately commenced
high-dose CoQ10 treatment (20 mg/kg/day), the infant’s
status rapidly deteriorated, probably because of the intrac-
table albumin loss and pulmonary hypertension. Within
2 weeks, he developed kidney failure and anuria, which
required hemodialysis. He was put on mechanical venti-
lation, with inhalative nitrous oxide treatment. In spite of
major treatment efforts, he died 1 month after admission.
Genetic analyses
We performed Illumina TruSight One clinical-exome se-
quencing, involving the genes related to CoQ10 synthesis
(COQ2 , COQ4 , COQ6 , COQ7 , COQ8A , COQ8B
[ADCK4], COQ9, PDSS1, PDSS2, ADCK1, ADCK2,
ADCK5, COQ3, COQ10A, COQ10B, FDXR, FDX2,
ATPX, BRAF, ETFDH) and those involved in the patho-
genesis of infantile nephrotic syndrome, such as ACTN4,
ARHGAP24, CD2AP, CFH, CUBN, DGKE, INF2, ITGA3,
ITGB4, KANK1, LAMB2, LMX1B, MYH9, MYO1E,
NPHS1 , NPHS2 , PLCE1 , PTPRO , SCARB2 ,
SMARCAL1, TRPC6, and WT1.
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A heterozygous missense mutation in the PDSS2 gene in
exon 3 was found that could have caused a defect in mito-
chondrial ATP production (Fig. 1a). PDSS2 exon 3
c.485A > G, p.His162Arg mutation has a SIFT prediction
Bdeleterious^ (0) and a PolyPhen prediction Bprobably
damaging^ (1) [9, 10]. The 162 His amino acid is conserved
among the vertebrae (H short for His is highlighted in red in
Fig. 1b) and since the PhyloP conservation score is 4.71, this
indicates a conserved site [11].
Our database contains the coverage data of 200 TruSight
One runs that were performed on the same platform, machine,
wetlab protocols, and bioinformatic analysis pipeline. The hy-
bridization protocol used for TruSight One ensures nearly lin-
ear target enrichment; thus, the only complications that could
arise would be due to GC bias and wetlab errors, which result
in significantly altered insert sizes or low coverage. Our in-
house joint-analysis algorithm is based on the following
principles:
1. We assessed the wetlab QC values and the overall vari-
ability of the coverage profile for each sample to deter-
mine whether the sample is suitable for CNVanalysis
2. Using the coverage profile of QC-passed samples for each
bed coordinate, the log3 normalized average coverage and
the variance of coverage were calculated using the bedcov
algorithm of samtools (version 1.3.1–50-gd02c177) [12]
3. Depending on the average coverage and variance, the re-
gions were classified into normal, null coverage, low
Fig. 1 PDSS2 mutations in exon
3 and in exon 8. a PDSS2
mutation in exon 3. A single
nucleotide change c.485A > G
identified in our patient and in the
carrier mother (R indicating the
heterozygous A/G state) whereas
the father was homozygous for
normal c.485A allels. b The 162
His amino acid is conserved
among the vertebrae (H
highlighted in red) An alignment
showing the relevant part of
PDSS2 protein in six vertebrate
species. c A heterozygous 2923-
bp deletion identified in our
patient and in the carrier father.
The Sanger traces show the
deletion breakpoint (indicated by
a red arrow) within exon 8, in the
case of the index patient and his
father, whereas the unaffected
maternal sequence is shown for
comparison
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normalized average coverage categories indicating no
CNV, homozygous deletion, heterozygous deletion, and
duplication respectively
4. Potential CNV alterations in the disease-specific genes
were checked individually
Using our algorithm, we detected a heterozygous 2923-bp
deletion that affected a part of the last exon (exon 8) in the
PDSS2 gene (Fig. 1c). At the time, we did not find any other
pathological alteration in the CoQ10 or nephrotic-related
genes in question. We validated both mutations by Sanger
sequencing in the patient sample using the following primer
pairs (PDSS2_IVS7-Ex8F 5-CTCCAGCCTGGGTG
ATAGAG-3, PDSS2_IVS7-Ex8R 5-GCTCCCAATCAACC
TCATTC-3, PDSS2-Ex3F 5-TTACAGATCCCAAA
CTGCTCA-3, and PDSS2-Ex3R 5-AGCTCCAGCAGCCA
ACTAAT-3).
The parental carrier analysis confirmed that the maternal
mutation is the NM_020381.3:c.485A > G (p.His162Arg)
variant in exon 3 (Fig. 1a) and that the paternal allele is the
NM_020381.3:c.1042_1148-2816del, which causes a 107-
base long deletion of exon 8 (Fig. 1c).
Neither mutation was found in the ExAC database [13]
(more than 120,000 chromosomes) nor among 400 population
control (Hungarian) chromosomes. Both mutations were lo-
cated within the highly conserved and essential polyprenyl
synthase domain, spanning amino acids (AA) 58–397. The
exact molecular effect of the paternal deletion has not been
investigated owing to a lack of further cooperation; thus, we
use the notation p.? to indicate that an effect at the protein
level is expected, but it is not possible to give a reliable mo-
lecular prediction of the consequences.
Results
At autopsy, an external inspection revealed generalized sub-
cutaneous edema with moderate hydrocele. The following
body and organ weights were noted: whole body 6,420 g,
brain 788 g, heart 44 g, lungs 115 g, kidneys 144 g, liver
250 g, spleen 19 g, and thymus 4 g. The main macroscopic
alterations included symmetrically and markedly enlarged
kidneys, a hypertrophic left ventricle, and consolidated lung
lobes. There was no significant abnormality in the cerebral
cortex, the basal ganglia, the brainstem, the cerebellum, or
the spinal cord. The ventricles appeared to be slightly dilated.
The cranial nerves did not display any change and the eyeballs
were normal-sized.
Formalin-fixed paraffin-embedded tissue sections stained
with hematoxylin-eosin were made for a histological evalua-
tion of the bone marrow, the thymus, the lymph node, the
gastrointestinal tract, the pancreas, the endocrine organs, the
skeletal muscles (diaphragm, intercostal muscle, quadriceps),
the urinary bladder, and testicles. A detailed neuropathologi-
cal examination of the central nervous system was performed
by the neuropathologist coauthor (IB) on a total of 25 blocks
from the brain and the spinal cord. The kidney tissue samples
were examined by special stains (PAS, trichrome, and methe-
namine silver of Jones), immunofluorescence of frozen sec-
tions (IgG, IgA, IgM, kappa, lambda, C3, C1q, and fibrino-
gen), and by electron microscopy. The immunophenotype of
glomerular epithelial cells was studied using antibodies
against Wilms tumor-1 (WT1; marker of mature podocytes;
Cell Marque, Rocklin, CA, USA; clone 6F–H2; an antibody
dilution 1:300, pH 6), PAX2 (marker of parietal epithelial
cells; Abgent, San Diego, CA, USA; clone EP3251; dilution
1:250, pH 9), cytokeratins (AE1/AE3 cocktail; Cell Marque;
dilution 1:300, pH 9) and Ki-67 (proliferation marker;
Biocare, Pacheco, CA, USA; clone SP6; dilution 1:100,
pH 6) on paraffin sections.
Histologically, the glomeruli in the subcapsular cortex ap-
peared fetal (Fig. 2a). The corpuscles in the deeper cortex
were larger and more mature, and exhibited three types of
lesions. The first type consisted of an increase in the mesangial
matrix, occasionally accompanied by mild mesangial
hypercellularity. The second type was characterized by the
combination of thickened, sometimes double-contoured, glo-
merular basement membrane (GBM) and a marked expansion
of the mesangium (trichrome: blue, silver: positive) leading to
the closure of the capillary tufts. Enlarged podocytes covered
the consolidated areas (Fig. 2b–d). The third type, affecting a
few glomeruli, manifested in the shrunken solidified glomer-
uli, covered by a corona of epithelial cells (Fig. 2e).
Pseudocrescents or sclerosing capsular adhesions were not
observed. The tubuli appeared to be dilated, but cystically
dilated profiles were not observed. Signs of acute kidney in-
jury (i.e., mitoses in tubular epithelial cells, distal tubular
casts, and granulocytic and erythroid precursors in the vasa
recta) were not seen. Mild focal interstitial fibrosis and tubular
atrophy accompanied the glomerular alterations (Fig. 2a, b).
However, the arteries and arterioles were normal. As regards
the immunophenotype of glomerular epithelial cells, the
podocytes and the parietal epithelial cells did not react with
the AE1/AE3 cytokeratin cocktail (Fig. 2f). The WT1 stain-
ing, which diffusely decorated the cytoplasm of podocytes in
the subcapsular cortex (Fig. 3a), proved focally negative at
sites of capillary consolidation (Fig. 3b). By contrast, some
of the podocytes covering the consolidated regions expressed
PAX2 positivity (Fig. 3d). The Ki-67-staining in podocytes
revealed 0 to 4 signals in a glomerular profile (Fig. 3c). An
immunofluorescence examination of the glomeruli proved
negative. Six glomeruli were evaluated ultrastructurally.
Although the postmortem conditions limited the assessment
of the fine structure of the cell organelles, the alterations in the
GBM could be unambiguously discerned. Effacement of foot
processes was seen in about 70% of the circumference of
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capillary tufts. Capillary tuft consolidation was observed in 2
of the 6 glomeruli. In these sites, the podocytes were enlarged
and contained many dense vacuoles, and several layers of
basement membrane material were deposited in the
subepithelial and subendothelial space of the capillary wall
(Fig. 4). The mesangial cells were enlarged and were
surrounded by an abundant mesangial matrix. Mitochondrial
inclusion bodies were not observed in the cells of glomerular
and tubular profiles. The glomerular alterations detailed above
were consistent with diffuse mesangial sclerosis (DMS).
The cortical lamination, the visual cortex, the optic nerves,
and all structures of the brain and brainstem appeared to be
histologically normal. A histological evaluation of the left
ventricular myocardium revealed pronounced cardiomyocyte
hypertrophy, with the periodic acid-Schiff-negative
perinuclear clearing of the sarcoplasm. Some myofiber disar-
ray was definitely observed, and the interstitium lacked colla-
gen deposits. The findings were compatible with the clinical
diagnosis of hypertrophic cardiomyopathy. The lung sections
displayed diffuse alveolar damage, with widespread formation
of hyaline membranes. Also, microscopic foci of bacterial
pneumonia were present. The serological search for causative
agents of atypical pneumonia, such as CMV, Mycoplasma,
RSV, EBV, HSV1, HSV2, Parvo B19, and Pneumocystis
jiroveci proved negative and, therefore, the alveolar damage
was viewed as a consequence of the severe nephrotic syn-
drome and cardiomyopathy-induced pulmonary hypertension.
A histological evaluation of other organs and tissues did not
reveal any abnormality.
Fig. 2 Histological features of the glomeruli, tubuli, and interstitium in
PDSS2mutation. a Subcapsular cortex: the prominence of closely spaced
podocytes gives the glomeruli a fetal appearance. The tubuli and the
interstitium display no alteration (PAS). b Glomeruli from the deep
cortex: segmental closure of capillary tufts covered by enlarged
podocytes. The tubuli and the interstitium do not show any remarkable
alteration (PAS). c and d Diffuse mesangial sclerosis, the fully developed
stage: segmental consolidation of the capillary tufts covered by enlarged
podocytes (arrow). (c PAS, d Jones’ silver). eDiffuse mesangial sclerosis,
the advanced stage: a solidified glomerular profile with the disappearance
of glomerular tufts, and a corona of epithelial cells (arrow) (trichrome). f
The podocytes and the parietal epithelial cells do not express AE1/AE3-
positive cytokeratins
Fig. 3 Dysregulated podocytes in diffuse mesangial sclerosis. a
Podocytes in fetal-like glomeruli display uniform cytoplasmic positivity
with the WT1 staining. b By contrast, some of the epithelial cells
overlying the collapsed capillaries appear to be WT1-negative. c The
proliferation marker Ki-67 commonly exhibits nuclear positivity in cells
opposite the urinary space. d Nuclear PAX2 positivity in cells covering
the sclerosed glomerular segment and in the cells of Bowman’s capsule
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Discussion
Pathogenic mutations in mitochondrial disease may occur in
the nuclear genes or the mitochondrial genes [14]. The CoQ10
biosynthesis pathway is encoded by nuclear genes. An early
diagnosis is crucial because an oral administration with high-
dose CoQ10 can improve the clinical symptoms. However,
obtaining a clear diagnosis is not easy and necessitates bio-
chemical and/or genetic studies. A biochemical diagnosis of
CoQ10 deficiency can be established by measuring the CoQ10
content in cultured skin fibroblasts or skeletal muscle biopsies
[7]. Usually, routine morphological studies onmuscle sections
do not yield specific findings; we had a similar experience
with our patient during an evaluation of the skeletal muscle
samples. Although deafness and retinitis pigmentosa were
suspected clinically, a detailed neuropathological examination
of the central nervous system did not reveal any significant
alterations. The definite diagnosis in our patient, namely that a
PDSS2 mutation was the ultimate cause of the CoQ10 defi-
ciency, was achieved via the Illumina TruSight One clinical-
exome sequencing and by applying our in-house joint-analy-
sis algorithm, which together revealed two hitherto unknown
mutations located within the polyprenyl synthetase domain. It
should be mentioned here that large-scale deletions can easily
be overlooked by standardmutation screening protocols as the
size of the deletion—which was in our case 2923 bp—is more
than ten times larger than the reading length (2 × 150 bp) and
most of the bed coordinate-based algorithms used in exome
kits filter out deletions starting in the deep intronic regions
because exome sequencing only focuses on the exons and
short intronic (splicing) regions around the exons.
Regarding the features of PDSS2 mutations published so
far, the analysis in an infant with the Leigh syndrome and
nephrotic syndrome performed by López et al. [7] identified
a heterozygous C/T transition at nucleotide 964, changing
amino acid 322 from glutamine to a stop codon and a hetero-
zygous C/T transition at nucleotide 1145, changing amino
acid 382 from serine to leucine in the seventh conserved do-
main in transprenyl diphosphate synthase. In the study by
Sadowski et al. on the single-gene cause of the steroid-
resistant nephrotic syndrome in 1,783 unrelated families, 2
infants had PDSS2 homozygous mutations (c.1145C > T,
p.Ser382Leu and c.1151C > A, p.Ala384Asp) [8].
Interestingly, PDSS1-mutant patients seem to have a differ-
ent clinical presentation than those with PDSS2 mutations,
even though both mutations cause a transprenyltransferase
deficiency. Mollet et al. evaluated a boy and his sister affected
by COQ10 deficiency [15]. They were born from the marriage
of first cousins. Both were normal at birth, but then developed
deafness, optic atrophy, obesity, macrocephaly, livedo
reticularis, cardiac valvulopathy, and mild mental retardation,
and both had a prolonged lifespan. Lactate in plasma was
mildly elevated. Their disease was attributed to a homozygous
missense mutation in PDSS1 (c.977 T > G, p.Asp308Glu).
Vasta et al. performed targeted next-generation sequencing
on 26 patients with known or suspected mitochondrial disor-
ders [16]. An infant girl with COQ10 deficiency, developmen-
tal delay, nephrotic syndrome, leukoencephalopathy, lactate
peak, and failure to thrive was found to suffer from a PDSS1
mutation characterized by a compound heterozygote with two
novel variants in prenyl (decaprenyl) diphosphate synthase,
subunit 1 (c. 661C > CT; p.Arg221Term and c.1108A > AC;
p.Ser370Arg). The kidney biopsy revealed acute tubular epi-
thelial damage. The patient died at 16 months of age because
of renal failure.
In our patient, the negativity of the glomeruli on immuno-
fluorescence, along with the focal segmental collapse of glo-
merular capillary tufts and enlarged, proliferating podocytes
covering the consolidated areas suggested two possibilities,
namely DMS or collapsing glomerulopathy as the cause of
the infantile-onset nephrotic syndrome. DMS was concluded
based on three findings. First, the combination of fetal-looking
glomeruli and more matured glomeruli exhibiting three types
of lesions was similar to that observed in glomerular disorders
associated with the mutations of the Wilms’ tumor suppressor
gene, e.g., Denys–Drash syndrome and isolated DMS [17];
however, in our case, the deepest glomeruli were the most
severely affected. Second, an evaluation under electron mi-
croscopy of glomeruli demonstrated the lamellation of the
GBM, which has been regarded as the distinctive ultrastruc-
tural lesion of DMS [18]. Third, the aberrant AE1/AE3 ex-
pression of podocytes and parietal epithelial cells, character-
istic of primary focal–segmental glomerulosclerosis, includ-
ing the collapsing variant, was not encountered at all [19].
Fig. 4 Portion of a solidified glomerular segment observed using
electron microscopy. Several layers of basement membrane material
(asterisks) were deposited between the lamina densa of the glomerular
basement membrane (arrowhead) and the hypertrophied podocyte (P).
The widening of the subendothelial space was caused by the
accumulation of extracellular matrix material. M mesangial cell, ×2,500
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During nephrogenesis, the podocytes differentiate from an
epithelial to a mesenchymal phenotype, characterized by the
expression of mature podocyte markers, such as the WT-1
protein, the disappearance of expression of desmosomal pro-
teins, cytokeratin and PAX2, and the loss of proliferation
markers [20]. Studies on podocyte proliferation and pheno-
type in Denys–Drash syndrome, isolated DMS, collapsing
glomerulopathy, and HIV-associated nephropathy have re-
vealed that in these disorders the podocytes re-express prolif-
eration markers, and become focally negative for WT-1 and
positive for PAX2 [17, 21, 22]. A similar dysregulation of the
podocyte phenotype and proliferation was noted in our pa-
tient, suggesting that whatever the etiology, a common phe-
notypic response occurs in podocytopathies with collapsing
lesions. Nevertheless, the lesions of DMS per se did not seem
to be responsible for the rapid deterioration in the renal func-
tion of our patient that culminated in anuria.
A morphologically similar glomerular disease called col-
lapsing glomerulopathy developed in kd/kdmice with a Pdss2
gene mutation [21]. The kd/kd mouse model of collapsing
glomerulopathy led Gasser et al. to hypothesize that human
PDSS2 polymorphism might be associated with podocyte dis-
eases [23]. The authors genotyped 9 single-nucleotide poly-
morphisms in the PDSS2 gene in 377 patients with primary
focal segmental glomerulosclerosis. Among European–
American patients, a pair of proxy single-nucleotide polymor-
phisms was significantly associated with podocyte disease,
and patients homozygous for one PDSS2 haplotype had a
greatly increased risk of podocyte disease. In contrast, the
distribution of PDSS2 genotypes and haplotypes was similar
in Afro-American patients and controls. Thus, a PDSS2 hap-
lotype is associated with an increased risk for focal segmental
glomerulosclerosis in European–Americans.
Conclusion
Our case presentation extended medical knowledge on the
clinicopathological spectrum of PDSS2 mutation-induced
podocyte mitochondriopathy, and described two new patho-
genic mutations in the PDSS2 gene that both affected the
polyprenyl synthetase domain. The mutations lead to
infantile-onset multisystemic disease. Regrettably, the
multiorgan dysfunction in our patient did not show any signs
of improvement following the administration of high-dose
CoQ10. We do not know whether the failure of treatment
was due to the poor bioavailability of the CoQ10 that was
administered, or whether other disturbed physiological func-
tions of CoQ10 played a part in the progressive nature of the
disease. Based on the findings of the genetic analysis present-
ed above, a prenatal genetic test was offered within the frame-
work of genetic counseling to this couple. An analysis of the
fetal DNA obtained from a chorionic villus biopsy detected
only the maternal PDSS2 mutation. The carrier baby, in com-
pliance with the inheritance model of PDSS2, was born
healthy.
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